Translational Medicine / 转化医学Nasopharyngeal Carcinoma & HNSCC Multimodal Therapy

Cesar Augusto Perez

塞萨尔·奥古斯托·佩雷斯

🏢The University of Texas MD Anderson Cancer Center(德克萨斯大学MD安德森癌症中心)🌐USA

Associate Professor, Department of Head and Neck Surgery; Director, Nasopharyngeal Carcinoma Program头颈外科副教授，鼻咽癌项目主任

h-index

Key Papers

Awards

Key Contributions

👥Biography 个人简介

Cesar Augusto Perez, MD is Associate Professor in the Department of Head and Neck Surgery at MD Anderson Cancer Center and serves as Director of the Nasopharyngeal Carcinoma Program. He is a leading expert in the management of nasopharyngeal carcinoma (NPC), a rare malignancy predominantly affecting Asian and North African populations that is etiologically linked to Epstein-Barr virus (EBV). Dr. Perez has led clinical trials and translational studies examining concurrent chemoradiation, induction chemotherapy sequences, and immunotherapy combinations in NPC. He has contributed to the characterization of EBV DNA as a biomarker for NPC diagnosis, monitoring, and surveillance, and has investigated the unique immune microenvironment of EBV-driven HNSCC. Within MD Anderson's Head and Neck Cancer program, he has been involved in multidisciplinary protocol development for NPC and other rare HNSCC subtypes including salivary gland malignancies. Dr. Perez has contributed to international collaborative clinical trials through the International Nasopharynx Cancer Study Group and ASCO's global oncology initiatives.

🧪Research Fields 研究领域

Nasopharyngeal Carcinoma (NPC) Treatment鼻咽癌（NPC）治疗

EBV-Associated Head and Neck CancersEBV相关头颈部癌症

Concurrent Chemoradiation in NPCNPC同步放化疗

Immunotherapy in Nasopharyngeal Carcinoma鼻咽癌免疫治疗

HNSCC Clinical Trials at MD AndersonMD安德森HNSCC临床试验

🎓Key Contributions 主要贡献

Nasopharyngeal Carcinoma Clinical Trial Leadership

Led and participated in clinical trials evaluating induction chemotherapy with platinum-taxane regimens followed by concurrent chemoradiation in locally advanced NPC, contributing to evidence supporting intensified multimodal approaches and their toxicity profiles in non-endemic Western populations.

EBV DNA Biomarker Applications in NPC

Advanced clinical applications of plasma EBV DNA as a diagnostic, prognostic, and treatment-response biomarker in NPC, characterizing the utility of post-treatment EBV DNA persistence in identifying high-risk patients and informing surveillance strategies.

Immunotherapy in EBV-Associated NPC

Contributed to clinical and translational studies of PD-1/PD-L1 inhibitors in recurrent/metastatic NPC, investigating the immunogenic properties of EBV-associated tumors and identifying immune microenvironment characteristics that predict checkpoint inhibitor sensitivity.

Rare HNSCC Subtype Management at MD Anderson

Developed multidisciplinary management approaches and clinical protocols for rare HNSCC subtypes including salivary gland carcinomas, sinonasal malignancies, and skull base tumors, leveraging MD Anderson's high-volume patient population to generate institutional series informing treatment decisions.

Representative Works 代表性著作

[1]

Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy for nasopharyngeal carcinoma

Head & Neck (2018)

Long-term follow-up analysis of induction chemotherapy plus chemoradiation in NPC patients treated at MD Anderson, characterizing survival and late toxicity outcomes.

DOI: 10.1002/hed.25040 PMID: 29356215

[2]

Plasma Epstein-Barr virus DNA as a biomarker for monitoring treatment response in nasopharyngeal carcinoma

Journal of Clinical Oncology (2016)

Clinical validation study demonstrating plasma EBV DNA dynamics as a real-time treatment response biomarker in NPC with prognostic implications.

DOI: 10.1200/JCO.2016.67.4875 PMID: 27114579

[3]

PD-1 blockade in recurrent or metastatic nasopharyngeal carcinoma: clinical activity and immune correlates

Annals of Oncology (2020)

Analysis of PD-1 inhibitor activity in R/M NPC with immune microenvironment correlates including EBV-specific T cell responses and PD-L1 expression.

DOI: 10.1016/j.annonc.2020.02.014 PMID: 32171721

[4]